Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
On December 19, 2016, Sucampo Pharmaceuticals, Inc. the
Registrant) issued a press release
announcing its intention to offer, subject to market and other
conditions, $225.0 million principal amount of convertible senior
notes due 2021 (the Notes) in a private
offering (the Note Offering) to
qualified institutional buyers to Rule 144A of the Securities Act
of 1933, as amended (the Securities
Act). The Registrant also expects to grant the
initial purchasers of the Notes a 13-day option to purchase up to
an additional $33.75 million principal amount of Notes, solely to
cover over-allotments, if any. Copies of this press release and
the slides that the Registrant expects to use in connection with
the marketing of the Note Offering are furnished herewith as
Exhibits99.1 and 99.2 to this Current Report on Form 8-K,
respectively, and are incorporated herein by reference.
The information in this Item 7.01 of this Current Report on
Form8-K (including Exhibits99.1 and 99.2) is being furnished and
shall not be deemed filed for purposes of Section18 of the
Securities Exchange Act of 1934, as amended (the
Exchange Act), or otherwise subject to
the liabilities of that Section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act,
or the Exchange Act, except as expressly set forth by specific
reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
| Exhibit Number | ExhibitDescription | |
| 99.1 |
Press Release, dated December 19, 2016, titled Sucampo Announces Proposed Convertible Senior Note Offering. |
|
| 99.2 |
Slide Presentation, titled Sucampo Pharmaceuticals, Inc. Corporate Update. |
|
About Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom. It offers AMITIZA for the treatment of constipation and RESCULA for the lowering of intraocular pressure (IOP). Its products under development include cobiprostone, RTU-1096 and RTU-009. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Recent Trading Information
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) closed its last trading session up +0.95 at 16.70 with 715,109 shares trading hands.
